From our private database of 30,900+ case briefs...
Sanofi-Synthelabo v. Apotex, Inc.
United States Court of Appeals for the Federal Circuit
470 F.3d 1368 (Fed Cir. 2006)
Sanofi-Synthelabo (“Sanofi”) (plaintiff) held the ‘265 patent to clopidogrel bisulfate, the active ingredient in the heart attack and stroke reducing drug, Plavix® which Sanofi also marketed. In November 2001, Apotex, Inc. (“Apotex”) (defendant) filed an Abbreviated New Drug Application (“ANDA”) in order to obtain Food and Drug Administration (“FDA”) approval to manufacture and market a generic version of Plavix®. As part of the ANDA, Apotex filed a Paragraph IV certification asserting that the ‘265 patent was invalid. Sanofi filed suit against Apotex in the U.S. District Court for the Southern District of New York, claiming that the Apotex’s ANDA filing infringed on the ‘265 patent. The filing of the suit triggered a 30-month stay of FDA approval of Apotex’s ANDA. Apotex then counterclaimed, asserting that the ‘265 patent was invalid and unenforceable. The stay expired May 17, 2005, and on January 20, 2006, the FDA approved Apotex’s ANDA. On August 8, 2006, Apotex launched its generic version of Plavix® and Sanofi thereafter filed a motion for a preliminary injunction on August 15, 2006, to prevent Apotex from selling the generic drug and to recall any disbursed shipments of the drug. The district court granted Sanofi’s motion for a preliminary injunction, but denied its recall request on August 31, 2006. Between Apotex’s August 8 launch and the court’s order of August 31, Apotex had shipped a six-month supply of the drug to distributors nationwide. In granting Sanofi’s request for injunctive relief, the district court relied on an established and commonly-used four-factor test. The court then set bond in the amount of $400 million. Apotex appealed the district court’s grant of the preliminary injunction.
Rule of Law
Holding and Reasoning (Lourie, J.)
What to do next…
Unlock this case brief with a free (no-commitment) trial membership of Quimbee.
You’ll be in good company: Quimbee is one of the most widely used and trusted sites for law students, serving more than 552,000 law students since 2011. Some law schools—such as Yale, Berkeley, and Northwestern—even subscribe directly to Quimbee for all their law students.Unlock this case briefRead our student testimonials
Learn more about Quimbee’s unique (and proven) approach to achieving great grades at law school.
Quimbee is a company hell-bent on one thing: helping you get an “A” in every course you take in law school, so you can graduate at the top of your class and get a high-paying law job. We’re not just a study aid for law students; we’re the study aid for law students.Learn about our approachRead more about Quimbee
Here's why 552,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 30,900 briefs, keyed to 984 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.